Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2014-10-30 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science EN
Regulatory Filings Classification · 90% confidence The document is an announcement from AB Science SA dated October 30, 2014, detailing the 'Publication of preclinical data on the neuroprotective effect of masitinib' in a peer-reviewed journal. It summarizes findings and discusses the implications for neurodegenerative diseases. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific/research findings relevant to investors, but it does not fit the definitions for Investor Presentation (IP), Management Discussion (MDA), or Audit Report (AR). Since it is a specific announcement regarding research results and scientific progress, and it is not a standard financial report, it falls best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate communication, or potentially a specialized Investor Relations document. Given the options, RNS serves as the best catch-all for specific, non-standard corporate updates that aren't explicitly defined elsewhere, especially when the content is scientific rather than purely financial or governance-related. However, since it is a specific announcement about research progress, which is crucial for investors, and it is not a standard financial report, RNS is the most appropriate fallback.
2014-10-30 English
AB Science EN
Earnings Release Classification · 99% confidence The document explicitly states it reports 'Quarterly information – 3rd quarter 2014' and provides key financial metrics like 'Turnover' and 'Cash position' as of September 30, 2014. It details financial performance for a period shorter than a year (Q3) and includes operational updates. This structure aligns perfectly with a comprehensive financial report for an interim period, which corresponds to the Interim / Quarterly Report category (IR). It is not just an 'Earnings Release' (ER) as it contains detailed financial position updates and significant operational/clinical trial progress, making it more comprehensive than a simple highlights announcement. Q3 2014
2014-10-15 English
AB Science FR
Interim / Quarterly Report Classification · 95% confidence The document is an official announcement from AB Science regarding its financial results for the third quarter of 2014. It includes specific revenue figures, cash position, and business highlights (clinical trial updates). It is a periodic financial update that provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q3 2014
2014-10-15 French
Résultats financiers T2
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Semi-annual Financial Report) for AB Science S.A. as of June 30, 2014. It contains a declaration by the CEO, a detailed management report on activities, and comprehensive financial statements (income statement, operational results, and cash flow analysis). Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H2 2014
2014-10-07 French
AB Science FR
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 30, 2014, from AB Science SA. It announces that the Independent Data Review Committee recommended the continuation of a Phase 3 clinical study for masitinib in treating mastocytosis based on efficacy and tolerability data. This type of announcement, detailing clinical trial progress, regulatory/committee feedback, and future expectations (final results expected in 2015), is characteristic of an update intended for investors and the market regarding ongoing development activities. It is not a full financial report (10-K or IR), a transcript (CT), or a formal dividend/share change notice. It most closely aligns with an announcement related to drug development progress, which often falls under general investor relations updates. Given the options, it is a specific corporate update that doesn't fit the strict definitions of ER, AR, or CT. Since it is a detailed update on a specific drug development milestone, it is best classified as an Investor Presentation (IP) if it were a slide deck, but as a press release detailing clinical progress, it functions as a key piece of information for investors. However, looking at the provided definitions, there isn't a perfect fit for a 'Clinical Trial Update'. It is not a formal Earnings Release (ER), nor a comprehensive Interim Report (IR). Since it is a detailed announcement about the company's core business (drug development) aimed at the market, and it is not a formal regulatory filing like a 10-K, the closest category that captures significant corporate/development news that isn't strictly financial reporting or a formal meeting material is often grouped with Investor Presentations or general Regulatory Filings (RNS). Given the detailed nature of the scientific update, it functions similarly to an Investor Presentation (IP) in terms of content focus, but it is structured as a press release. Since it is a detailed update on the company's pipeline progress, which is crucial for investors, and it is not a short announcement pointing to another document (RPA), I will classify it as an Investor Presentation (IP) as it presents detailed information about the product's status and potential, which is the core function of an IP, even if the format is a press release. If 'IP' is too narrow, 'RNS' is the fallback. Given the depth of the scientific and trial information, IP seems more appropriate than the generic RNS.
2014-09-30 French
AB Science EN
Investor Presentation Classification · 95% confidence The document is a press release dated September 30, 2014, from AB Science SA announcing that the Data and Safety Monitoring Board (DSMB) recommended the continuation of a phase 3 clinical study for their drug masitinib in mastocytosis based on safety and efficacy data. This content details clinical trial progress, scientific rationale, and company pipeline information, which is typical of an Investor Presentation (IP) or a general corporate update. Since it is a detailed announcement about ongoing clinical development and scientific findings rather than a formal regulatory filing (like 10-K or IR) or a simple earnings release (ER), 'Investor Presentation' (IP) is the most fitting category, as these announcements often serve as the basis for investor briefings or are released alongside presentations.
2014-09-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.